Articles

Despite improvements in the treatment of advanced ovarian cancer, less than half of newly diagnosed patients survive longer than 5 years, and relapse rates remain high. At the Society of Gynecologic Oncology (SGO) 2021 Virtual Annual Meeting on Women’s Cancer, experts presented updated results from 2 phase 3 clinical trials showing the benefit of the poly (ADP-ribose) polymerase (PARP) inhibitors olaparib (Lynparza) and niraparib (Zejula) as maintenance therapy in women with advanced or recurrent disease.

Cranbury, NJ - PM360, the premier information resource for marketing decision makers in the pharmaceutical, biotech, diagnostics, and medical device sectors, has named Burt Zweigenhaft, PhD, DLitt, Co-Founder, Association for Value-Based Cancer Care (AVBCC), as one of the 2021 PM360 ELITE 100 in the Master Educators category.

April 21, 2021, Cranbury, NJ - The Association for Value-Based Cancer Care (AVBCC) is honored to announce that Scott Gottlieb, MD, and Seema Verma, MPH, will be presenting together for a first-time keynote experience at the 11th Association for Value-Based Cancer Care Summit & Educational Program, taking place in New York, NY, on October 13-15, 2021.

The COVID-19 pandemic has had a profound impact on healthcare, especially in the management of patients with cancer, who are often not seeking healthcare in the same way as before the pandemic. At the 2021 International Association for the Study of Lung Cancer (IASLC) meeting, experts discussed the implications for patients with lung cancer, specifically.

The addition of the cyclin-dependent kinase (CDK)4/6 inhibitor abemaciclib (Verzenio) to standard endocrine therapy reduced the risk for invasive disease recurrence or death compared with endocrine therapy alone by almost 30% in patients with high-risk, hormone receptor (HR)-positive, HER2-negative early breast cancer. These results come from the primary analysis of the phase 3 monarchE clinical trial that was presented at the 2020 San Antonio Breast Cancer Symposium.